Rapport Therapeutics (RAPP)

• Market cap: $2.31B
• 1 day: 0.82%
• 5 days: 1.73%
• 1 month: 13.35%
• 3 months: 31.44%
• 6 months: 60.16%
• Year to date: 71.61%
• 1 year: 223.11%
• 5 years: 131.92%
• 10 years: 131.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Employees: 84